Technology
Learn more about Hexima’s technology.
HXP124
Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.
Latest news
Mr Scott Robertson appointed to Board of Directors
Hexima Limited has announced the appointment of Mr Scott Robertson to its Board of Directors, effective 21 November 2018. Speaking at Hexima’s recent AGM, Chairman Professor Jonathan West said “I am pleased to announce today that we will be adding Mr Scott Robertson...
AGM 2018 – Presentation and Results
Presentations and Results from the 2018 Hexima Limited Annual General Meeting held 20 November 2018. AGM 2018 Chairman’s Address AGM 2018 CEO & CSO Presentation AGM 2018 Meeting...
Hexima’s promising clinical trial results for HXP124 appear in Saturday’s Herald Sun newspaper
Hexima's Chief Science Officer Professor Marilyn Anderson and CEO Dr Nicole van der Weerden appeared in Saturday's Herald Sun newspaper on 3 November. The article follows our promising results from our clinical trial for HXP124 as a treatment for fungal nail...
Hexima announces positive results from Part 1 of phase 1/2a clinical trial of HXP124
Hexima is pleased to announce positive results from Part 1 of its ongoing phase 1/2a clinical trial for HXP124 as a novel topical treatment for fungal nail infections (onychomycosis). “HXP124 substantially reduced the area of infection in patients with a much shorter...
Chairman and CEO update
It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...
External Links
Take a look at these useful links to learn more about our industry.
